As a part of CPIC, Dr. Uppugunduri is involved in the development of a clinical guidelines for personalized proton pump inhibitor dosing based on CYP2C19 gene (in development). He is also a member of the educational division of European Society of Pharmacogenomics and Personalized Therapy (ESPT). Dr. Uppugunduri is involved in knowledge dissemination via virtual platforms for e.g. he founded a forum on personalized medicine earlier in nature work, and currently available at www.personalizedmedicine.in to engage researchers with similar interests and to have a dialogue.
Dr. Uppugunduri is currently working at Onco-Hematology unit, Department of Paediatrics, Gynaecology and Obstetrics, University of Geneva. He is also affiliated to a foundation supporting the research in pediatric onco-hematology (www.cansearch.ch). Dr. Uppugunduri is a recognized Clinical Pharmacologist (NON MD title by Swiss Society of Clinical Pharmacology and Toxicology) and participates in the implementation of therapeutic drug monitoring. He works with multidisciplinary team at his unit and laboratory, has strong collaboration with the teams of Clinical Pharmacology and Toxicology Division (https://www.hug-ge.ch/pharmacologie-toxicologie-cliniques) at University Hospitals of Geneva (University of Geneva). Dr. Uppugunduri is working with the objective of developing, evaluating, interpreting new/existing pharmacogenetics markers with clinical utility. He is also participating in teaching /education of medical doctors/allied health professionals in training on topics in clinical pharmacology and pharmacogenetics.
Dr. Chiara Fabbri is also a psychiatrist and she has worked mostly with patients having mood disorders at Bologna University (Italy) and in London (Affective Disorders Service, Maudsley Hospital). Knowing the clinical presentations of mood disorders and having direct contact with patients represent a great help in her everyday research work, in terms of motivation and expertise.
I have performed several retrospective analyses of clinical trial datasets to discover pharmacogenetic, pharmacokinetic, and pharmacometabolomic predictors of paclitaxel-induced peripheral neuropathy and am currently collecting and analyzing larger cooperative group clinical trial cohorts to validate these findings. One ongoing project that I am particularly excited is using our previously published neuropathy prediction model, which includes paclitaxel pharmacokinetics and dosing, and attempting to introduce genetics to explain residual variability in the “neuropathy sensitivity” phenotype. I also have ongoing work in the pharmacogenetics of hormonal treatment in breast cancer. I am currently leading a meta-analysis of all patient cohorts that have tamoxifen pharmacokinetic data and CYP2D6 genetic data to generate an endoxifen prediction algorithm and empirically derive estimates of the percentage activity of individual CYP2D6 alleles. I hope that this project will improve the accuracy of translating CYP2D6 genotype into predicted activity phenotype and produce a percentage phenotypic activity that is more intuitive for clinicians.
He is the co-editor of Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation (2nd edition), and his notable honors include the 2011 William Bowes Jr Award in Medical Genetics from Partners HealthCare Center for Personalized Genetic Medicine, and the 2012 Dr. Harold and Golden Lamport Research Award from the Icahn School of Medicine at Mount Sinai.
Her primary research interests are in the fields of pediatric cancer, pain, and pharmacogenomics. Dr. Haidar is the program coordinator for St. Jude’s ASHP-accredited PGY2 Clinical Pharmacogenomics Residency and is also an Assistant Professor of Clinical Pharmacy at The University of Tennessee Health Science Center. She is double board certified (BPS) in Pharmacotherapy and Oncology.
We expect to provide a comprehensive view of the ‘CYP3A interactome’, clarifying a substantial portion of CYP3A variability. The goal is to identify the main genetic and non-genetic determinants of CYP3A enzyme activity, with clinical utility as biomarkers guiding drug therapy. The approaches used in this project are broadly applicable to any genes of interest, to dissect complex genomic architecture, gene regulatory networks and discover genetic biomarkers for personalized drug therapy or disease prevention.
PGRN Hub & the Featured Investigator